Vestmark Advisory Solutions Inc. Has $5.71 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vestmark Advisory Solutions Inc. increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 15.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 845,154 shares of the company’s stock after purchasing an additional 112,221 shares during the period. Vestmark Advisory Solutions Inc. owned approximately 0.22% of Recursion Pharmaceuticals worth $5,713,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in RXRX. Charles Schwab Investment Management Inc. increased its stake in Recursion Pharmaceuticals by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after purchasing an additional 288,926 shares in the last quarter. Accel Wealth Management bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $310,000. FMR LLC lifted its holdings in shares of Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after purchasing an additional 170,810 shares in the last quarter. Avanza Fonder AB acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at $580,000. Finally, State Street Corp increased its stake in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $6.58 on Thursday. The firm has a market capitalization of $2.57 billion, a PE ratio of -4.30 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a 50 day moving average price of $7.68 and a 200-day moving average price of $7.08.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.42) earnings per share. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.